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Background: The aim of this study is to investigate the inter-scan reproducibility of kinetic parameters in
atherosclerotic plaque using dynamic contrast-enhanced (DCE) cardiovascular magnetic resonance (CMR) in a
multi-center setting at 3T.
Methods: Carotid arteries of 51 subjects from 15 sites were scanned twice within two weeks on 3T scanners using
a previously described DCE-CMR protocol. Imaging data with protocol compliance and sufficient image quality were
analyzed to generate kinetic parameters of vessel wall, expressed as transfer constant (Ktrans) and plasma volume
(vp). The inter-scan reproducibility was evaluated using intra-class correlation coefficient (ICC) and coefficient of
variation (CV). Power analysis was carried out to provide sample size estimations for future prospective study.
Results: Ten (19.6%) subjects were found to suffer from protocol violation, and another 6 (11.8%) had poor image
quality (n = 6) in at least one scan. In the 35 (68.6%) subjects with complete data, the ICCs of Ktrans and vp were 0.65
and 0.28, respectively. The CVs were 25% and 62%, respectively. The ICC and CV for vp improved to 0.73 and 28% in
larger lesions with analyzed area larger than 25 mm2. Power analysis based on the measured CV showed that 50
subjects per arm are sufficient to detect a 20% difference in change of Ktrans over time between treatment arms
with 80% power without consideration of the dropout rate.
Conclusion: The result of this study indicates that quantitative measurement from DCE-CMR is feasible to detect
changes with a relatively modest sample size in a prospective multi-center study despite the limitations. The relative
high dropout rate suggested the critical needs for intensive operator training, optimized imaging protocol, and
strict quality control in future studies.
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Neovasculature distributed inside the atherosclerotic
plaque is the primary route of inflammatory cell infiltra-
tion, a key process for plaque initiation, progression, and
rupture [1]. Plaque neovascularization and inflammation
are associated with clinical cardiovascular events caused* Correspondence: xzhao@cardiology.washington.edu
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unless otherwise stated.by atherosclerosis [2-4]. As a result, inflammation is an
emerging target for treatment in atherosclerosis [5,6]. To
assess and monitor the therapeutic effects of new treat-
ments, imaging techniques are needed that detect and
quantify neovascularization and inflammation in-vivo.
Dynamic Contrast-Enhanced (DCE) cardiovascular mag-
netic resonance (CMR) can quantify atherosclerotic angio-
genesis and inflammation in-vivo by measuring the
density and function of the neovasculature through kin-
etic modeling. Kinetic parameters, including fractionaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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trans),
have been found to be associated with histological mea-
surements of plaque neovasculature and macrophages
[7-9]. Based on this knowledge, DCE-CMR has been suc-
cessfully used in assessment of the therapeutic response of
the vasa vasorum in patients with atherosclerotic plaque,
including a decrease in Ktrans after 1-year intensive lipid
therapy [10]. Another study demonstrated the effect of pi-
oglitazone on atheroma by using DCE-CMR in an animal
model [11]. DCE-CMR was also utilized to monitor the
nature progression of atherosclerotic plaque [12].
For such studies, reproducibility of quantitative parame-
ters is key to study planning. However, the reproducibility
of the Ktrans and vp measurements of human vessel wall re-
mains largely unknown, especially for clinical studies in-
volving multiple imaging centers. This study sought to
investigate the inter-scan reproducibility of kinetic parame-
ters in atherosclerotic plaque using dynamic contrast-
enhanced (DCE) CMR in a multi-center setting at 3T.Methods
Study population
This study was performed with institutional review
board approval at each participating clinical site. Written
informed consent was obtained prior to study proce-
dures. Subjects who were enrolled in the Atherothrom-
bosis Intervention in Metabolic syndrome with low
HDL/high triglycerides: Impact on Global Health out-
comes (AIM-HIGH) trial [13] were asked for willingness
to participate in a MR reproducibility study. They were
45 and older, with dyslipidemia and clinically established
atherosclerotic disease in coronary, cerebrovascular/ca-
rotid and/or peripheral arteries [13]. Subjects with any
contraindication for MR examination or contrast injec-
tion were not included. Consented subjects underwent
two carotid MR examinations with two weeks, which in-
cluded a previously described DCE-CMR protocol. The
present study, as well as most previous studies, used a
bright-blood sequence for DCE-CMR [7-10], which does
not allow assessment of near-normal arteries due to con-
cerns of luminal signal contamination. Therefore, only
subjects with distinct carotid plaques were included, de-
fined as maximum wall thickness > 1 mm [14] measured
on pre-contrast T1-weighted MR with a customized
software (CASCADE) [15]. To ensure a multicenter de-
sign, each imaging site was restricted to a maximum of 6
subjects. From March 2009 to May 2012, of 47 subjects
screened, 33 AIM-HIGH subjects were enrolled at 10
imaging sites. We also screened 21 subjects and enrolled
18 subjects with the same inclusion and exclusion cri-
teria from 5 non-AIM-HIGH imaging sites to further in-
crease the number of sites and subjects. In total, 51
subjects from 15 imaging sites were included.This study was approved by the local IRB/RECs at
each participating clinical site. A signed informed con-
sent was obtained from participants.
Magnetic resonance imaging
All subjects were scanned twice within two weeks on 3T
MR scanners (GE HealthCare or Philips Healthcare) to
acquire carotid artery images using commercially avail-
able carotid phased-array coils (GE: 6-channel, Neocoil
LCC, Pewaukee, WI, USA; Philips: 8-channel, SHCG,
Shanghai, China). Each reproducibility scan was con-
ducted on the same scanner platform as the baseline
scan. The imaging protocol included an axial multi-slice
2D spoiled gradient recalled echo sequence to acquire
DCE images. On GE scanners 8 contiguous slices were
acquired, centered on the bifurcation of the index ca-
rotid artery to ensure the alignment between repeated
scans. The acquisition parameters were: field of view:
160*160 mm, matrix 256*256, imaging resolution:
0.625*0.625 mm, reconstructed image size 512*512,
2 mm slice thickness, repetition time 117 ms, echo time
5 ms, flip angle 50°. On Philips scanners, the protocol
was slightly different to ensure a similar coverage,
signal-to-noise ratio (SNR) and temporal/spatial reso-
lution: only 4 contiguous slices were acquired, also cen-
tered on the bifurcation of index side, with 3 mm slice
thickness, repetition time 126 ms. The index side was
defined as the side with larger plaque. Coincident with
the third dynamic scan in the sequence, 0.05 mmol/kg
of a gadolinium-based contrast agent (Magnevist, Bayer
Healthcare) was injected at a rate of 0.7 ml/s by a power
injector. The contrast dose and injection rate was selected
to avoid possible flow artifacts and weaken the require-
ment of high temporal resolution in DCE imaging [9]. Im-
ages were acquired at 18 time points separated by a
repetition interval of 18 s. To impose a T1-dependent sig-
nal on inflowing blood, a spatial saturation band was used.
Image analysis
A custom software (CASCADE) [15] was used for image
analysis. The DCE-CMR images were analyzed to gener-
ate vasa vasorum (V-V) images as previously described
[16]. This included registration and smoothing using
the Kalman filtering registration and smoothing algo-
rithm, extraction of the arterial input function, and cal-
culation of Ktrans and vp for each pixel based on the
Patlak kinetic model [17]. The resulting color-coded,
parametric V-V images show Ktrans in green and vp in
red (Figure 1), allowing single channel (green or red) to
be displayed. Next, the V-V image was outlined to define
the lumen boundary (the border of high vp values within
the lumen) and the outer wall boundary (the rim of high
Ktrans values representing adventitial enhancement) [18]
(Figure 1).
Figure 1 Representative scan-rescan V-V images (rows) of three plaques (columns). The white points indicate the carotid lumen; the white
arrows point to the outlined lumen and outer wall boundaries. Green indicates Ktrans with a range from 0 to 0.2 min−1 and red indicates vp with a
range from 0 to 1. Minor mis-resgistrations were occasionally present. The Ktran and vp values shown in each figure are the measurements of the
whole plaque.
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other scan and subject information. First, one trained re-
viewer (J. S., 3 years experiences in plaque analysis) identi-
fied all the boundaries on V-V images after checking the
protocol compliance. Then, a second reviewer (H. C.,
4 years experiences in plaque analysis) performed peer-
review of the boundaries defined by the primary reviewer.
Cases in which there was disagreement were discussed
with the primary reviewer to reach the consensus opinion.
Lastly, Ktrans and vp measurements were calculated by
averaging all pixels within the vessel wall, except for
those within 1 mm of the lumen contour (excluded
automatically by CASCADE). This exclusion minimized
any influence from the high intensity lumen signal in
bright-blood DCE images due to partial volume effects,
blurring, and motion.
Statistical analysis
The means of the scan 1 and scan 2 Ktrans and vp values
were compared using the paired t-test. The overall
between-scan reproducibility was estimated using a linear
mixed model. The reproducibility results are presented as
the between-scan standard deviation (SD), the between-
scan CV (between-scan SD divided by the grand mean)
[19] and the intra-class correlation (ICC). The 95% confi-
dence intervals for these three reproducibility statistics
were calculated using the non-parametric bootstrap. The
differences in means and between-scan SDs across the GE
and Phillips platforms were tested using the linear mixed
model and the permutation test, respectively.To explore the association of each subject’s between-
scan reproducibility with their plaque area we plotted
the subjects’ means and plaque sizes (the smaller of the
two scans’ plaque areas) against the subjects’ between-
scan SD. The association between the two factors and the
between-scan SD was tested using the Spearman correl-
ation (ρ) test. The least-squares fit was used to highlight
the trends in the scatter plots.
For each kinetic measurement, the CV estimate was
used to calculate sample sizes needed to detect differ-
ences in% changes (follow-up minus baseline, normal-
ized by the baseline mean) between two treatment arms.
The sample size calculations used the two-sided un-
paired t-test with 80% power and the 0.05 significance
level [20] without considering the exclusion rate. The
CV for the change (follow-up minus baseline) was calcu-
lated from the CV for a single time measurement (ob-
tained in the reproducibility analysis) by multiplying it
by √2. This calculation assumes that the measurement
error is the primary source of variability within each
treatment group (most importantly that the expected
treatment effect does not differ across patients).
The calculations were carried out in R (The R Founda-
tion for Statistical Computing, Vienna, Austria), version
2.15.2. A p-value less than 0.05 was used to denote statis-
tical significance.
Results
Of the 51 subjects included in this study, 10 (19.6%)
were excluded due to any significant violation of the
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correct time interval (n = 3), too few time frames (n = 2),
failure to inject contrast agent (n = 2) and improper
alignment of images (n = 3). Additionally, 6 (11.8%) sub-
jects were excluded for uninterpretable image quality in
at least one scan, generally due to severe subject motion
and/or low SNR. The remaining 35 (68.6%) subjects
were available for reproducibility assessment. These sub-
jects were from 14 sites with 2.5 ± 1.5 (mean ± standard
deviation) per site range (1 to 6). Demographic and clin-
ical characteristics of these subjects are given in Table 1.
DCE-CMR protocol non-compliance and image quality
issues were widely distributed across imaging sites. The 10
instances of protocol non-compliance were spread among
8 imaging sites and the 6 instances of poor image quality
were spread among 5 sites. No site accounted for more
than 2 exclusions due to protocol non-compliance and
image quality combined. Only in one site, all the scanned
subjects (2 subjects) were not included in the analysis due
to protocol non-compliance.
Figure 1 shows representative examples of the matched
V-V images for two scans of three carotid arteries, showing
Ktrans in green and vp in red. Mean K
trans and vp for the
first and second scan are compared in Table 2. Figure 2a
and b show the Bland-Altman plots of Ktrans and vp,
respectively.
Overall reproducibility parameters for Ktrans, and vp
are shown in Table 3. For Ktrans, the CV was 25% (95%
CI 15%-28%) and the ICC was 0.65 (95% CI 0.57-0.85)
suggesting moderate reproducibility of that parameter.
The parameter vp, on the other hand, exhibited substan-
tially worse reproducibility with a CV of 62% (95% CI
36%-73%) and ICC of 0.28 (95% CI 0.14-0.70). The
within-subject SD was not significantly related to the
mean value for both Ktrans (ρ = −0.02, p = 0.9, Figure 2c)
and vp (ρ = 0.25, p = 0.15, Figure 2d).
The poor performance of vp had a significant associ-
ation with plaque size exhibiting a negative Spearman
correlation (ρ = −0.45, p = 0.007; Figure 2f ). If subjectsTable 1 Demographic and clinical characteristics in 35
subjects included in reproducibility study
mean ± SD (range) or N (%)
Age (years) 61 ± 8 (45–79)
Gender (female) 12 (34%)
History of Myocardial Infarction 9 (26%)
History of Stroke 3 (9%)
History of Hypertension 28 (80%)
History of Diabetes 10 (29%)
LDL-C (mg/dl) 81 ± 34 (33–205)
Triglycerides (mg/dl) 163 ± 57 (80–349)
HDL-C, (mg/dl) 35.3 ± 6.1 (20.0-49.8)with analyzed areas smaller than 25 mm2 were excluded,
leaving 19 subjects for analysis, the CV and ICC for vp
improved to 28% (95% CI 18%-31%) and 0.73 (0.67-0.89),
respectively. The association between Ktrans reproducibil-
ity and plaque size showed only marginal significance
(ρ = −0.33, p = 0.06; Figure 2e). Little change in the ICC
and CV of Ktrans was observed for the 25 mm2 cutoff.
Based on the reproducibility results above, the sample
sizes needed to detect differences in change of each kin-
etic parameter between two treatment arms were com-
puted without considering the exclusion rate (Figure 3).
For Ktrans, 197, 50 and 23 subjects per arm would be
needed to detect differences of 10%, 20% and 30%, re-
spectively. For νp, 1224, 307 and 137 subjects per arm
would be needed, respectively. The required sample sizes
for νp reduced to 254, 64, and 29 if subjects with ana-
lyzed plaque areas less than 25 mm2 were excluded.
The use of 2 primary scanner platforms (GE and Philips)
allowed us to also evaluate whether these findings
depended on vendor. In total, 20 subjects scanned on
GE scanners were included in the study and 15 subjects
scanned on Philips scanners were included. As summa-
rized in Table 3, the differences in means, standard devi-
ations and CVs of kinetic parameters across platforms
were relatively small and not statistically significant.
Discussion
This study provides an evaluation of scan-rescan repro-
ducibility of kinetic parameters (Ktrans and vp) generated
from DCE-CMR using 3T MR scanners for multi-center
studies of carotid atherosclerosis. We found that Ktrans
had moderate but acceptable reproducibility in the
multi-center setting, with an overall CV of 25%. For this
level of reproducibility, a 20% greater relative reduction
in Ktrans could be detected with 80% power and p = 0.05
using 50 subjects per arm. Notably, a single arm study
involving 28 subjects on lipid lowering therapy using
similar techniques reported slightly greater than 20% re-
duction in Ktrans over a period of 1 year [10]. As a com-
parison for the reproducibility of vessel wall inflammation
quantification, a widely used serum-based inflammation
biomarker, high-sensitive C-Reactive Protein, showed a
large test-retest variation with CV of 46.2% [21].
For vp, on the other hand, the reproducibility was lower,
with an overall CV of 62%, indicating it is not a preferableTable 2 Comparison of kinetic parameters across scans
Mean (Standard deviation)
Scan 1 Scan 2 p‡
Ktrans* 0.061 (0.022) 0.063 (0.030) 0.6
vp
† 0.064 (0.053) 0.070 (0.046) 0.5
*Ktrans: transfer constant in min−1.
†vp: plasma volume fraction (unitless).
‡paired t-test.
Figure 2 Relationship of reproducibility with the mean measurement and with the plaque area. a. Bland-Altman plot of Ktrans.
b. Bland-Altman plot of vp. c. Per-subject mean K
trans (min−1) vs. per-subject between-scan SD of Ktrans (ρ = −0.02, p = 0.9), d. Per-subject mean vp
(unitless) vs. per-subject between-scan SD of vp (ρ = 0.25, p = 0.15). e. Plaque areas (on the log-scale) vs. per-subject between-scan SD of Ktrans
(ρ = −0.33, p = 0.06), f. Plaque areas (on the log-scale) vs. per-subject between-scan SD of vp (ρ = −0.45, p = 0.007). Dashed lines in panel (a) and
(b) indicate the mean differences and limits of agreement (±2 × SD of differences) for Bland-Altman plots. Solid lines in panels (d-f) are least
square fits. Fitted line in panel (d) excludes one outlier with mean vp above 0.20.
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vp, which represents tissue blood supply, is more vulner-
able to signal influences from lumen. The much higher
reproducibility, as shown in a subset of patients with
larger plaques, supports this hypothesis. Notably, previ-
ous histological validation studies [7-9] were all on pa-
tients with large lesions, further indicating vp is more
reliable parameter in large plaques. Additionally, the
limited temporal resolution may also introduce some
variance for vp [22]. As such, future studies involvinglimiting vp are suggested to use subjects with larger
lesions.
Of note, the reproducibility of DCE-CMR parameters
found in this multi-center experience is similar to that
reported in a recent single-center study [9]. In that
study, reported ICCs for Ktrans and vp were 0.79 and
0.48, respectively. CVs were 16% and 26%. The some-
what better reproducibility in that study may reflect the
use of a single imaging center. In addition, their popula-
tion included only subjects with at least 30% carotid
Table 3 Grand means, between-scan standard deviations
(SDs) and coefficients of variation for kinetic parameters
by vendor
Mean SD CV (%) (95% CI‡)
Ktrans*
All 0.062 0.015 25% (15%-28%)
GE 0.064 0.017 27% (16%-40%)
Philips 0.060 0.013 21% (10-22%)
p§ 0.6 0.12 0.12
vp
†
All 0.067 0.042 62% (36%-73%)
GE 0.068 0.042 62% (46-73%)
Philips 0.066 0.040 60% (18-71%)
p§ 0.8 0.9 0.9
*Ktrans: transfer constant in min−1.
†vp: plasma volume fraction (unitless).
‡CI : confidence interval.
§the linear mixed model test for the comparison of the means and the
permutation test for the comparison of the SDs and CVs (NS : p > 0.05).
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ger, more reproducible lesions.
Another key finding of this study involved the use of
both GE and Philips scanner platforms. Although each
subject was scanned on the same scanner, the measure-
ments and variability could have been platform dependent,
because the two platforms required slightly differentFigure 3 Sample size analysis. Sample size needed for each kinetic param
80% power using a two-sided unpaired t-test at the 0.05 significance level.
changes from 10% to 30% for Ktrans and vp, respectively.imaging protocols and coils. We found, however, no signifi-
cant differences in mean values or reproducibility metrics
when these two platforms were compared. This implies
that multi-center studies may not have to be restricted to a
single imaging platform.
To our best knowledge, this study is the first to study
the implementation of DCE-CMR in a multi-center set-
ting. We found that significant protocol violation in any
of the paired scans could affect as high as 20% of cases,
such as using incorrect time interval, insufficient time
frames, improper positioning of imaging slabs, and fail-
ure to inject contrast agent. Other than that, around
12% subjects were excluded because of poor imaging
quality. In this study, because sites were limited to no
more than 6 subjects, inexperience was likely a factor in
non-compliance. Moreover, the high rate of poor image
quality indicates that local operators have difficulties to
determine whether the scanned images have adequate
quality for quantitative analysis, because DCE-CMR needs
customized post-processing and modeling. For future
DCE-CMR studies, the following improvements are
needed to reduce the dropout rate: 1) optimization of the
experience of MR technologists performing the scans,
including more intensive hands-on training, mentoring
on subject instruction and provision of timely, ongoing
feedback for quality control; 2) technological advance-
ments including development of more rapid DCE-CMReter to detect a difference in% change between treatment arms with
The solid and dotted lines are the required sample sizes to detect
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struction methods, and improvement in imaging coil
design for deep carotid arteries; and 3) strict quality
control measures [23], including timely assessment of
image quality and imaging protocol adherence at the
central review site after post-processing, recall of sub-
jects with poor image quality or protocol violation for
repeat scan.
The source of the observed measurement variances
may relate to several factors that could also be addressed
for further improvement. First, patient positioning differ-
ences and subsequent image misregistration between the
two scans (Figure 1), even among different time points
in DCE series, may be an important factor, because the
imaging slice thickness (2 mm) is much larger than the
in-plane resolution (0.625 mm). Second, the relatively
low temporal resolution (18 s) can introduce variance
into the arterial input function extraction. However, the
specified spatial and temporal resolution used in this
study is a tradeoff with the SNR required to obtain ad-
equate image quality for DCE-CMR analysis. Patient move-
ment during DCE scan can cause blurring and artifacts in
images that affect the kinetic analysis. Coil placement dif-
ferences also can introduce variance. Finally, there may be
some natural variability between repeated scans due to per-
fusion regulation.
One technical limitation of this study is that current
analysis of bright-blood DCE images excluded a 1 mm
layer near the lumen boundary for measuring mean
Ktrans and vp, precluding the evaluation of thinner vessel
walls. However, this is a tradeoff to minimize the signal
contamination in the vessel wall from the high-intensity
lumen, which is a major difficulty in bright-blood DCE
imaging. Thus, studies using bright-blood DCE tech-
niques are more applicable to larger, more advanced le-
sions other than small early lesions. Recently proposed
black-blood DCE imaging technique may be a solution
for thin vessel walls [11,12,24]. This study was prospect-
ively designed to estimate scan-rescan measurement er-
rors that have potential utility for future serial imaging
studies. Image analysis followed the conventional way in
clinical trials where two readers analyze each case sequen-
tially to reach consensus opinion before measurement is
locked to avoid human errors and biases. Thus, intra- and
inter-reader reproducibility was not assessed. Compared
to inter-scan variability, reader variability may be a less
problem given that most post-processing steps of DCE-
CMR analysis are fully automated. Nonetheless, these
metrics need to be studied in future investigations before
the technique is used in the clinical setting.
Conclusions
This study is the first to establish scan-rescan reproduci-
bility and measurement variance of DCE-CMR of carotidatherosclerosis in a multi-center, multi-platform setting.
We found both Ktrans and vp derived from DCE-CMR,
have moderate reproducibility, the latter with lesions that
have a minimum analyzed area greater than 25 mm2.
Based on these findings, changes in Ktrans would be de-
tectable in a prospective study with relatively modest sam-
ple size, indicating that it is feasible to run multi-center
trials using vessel wall DCE-CMR. However, the rate of
uninterruptable images in this study highlights the need
for intensive operator training, optimized imaging proto-
cols timely, and ongoing quality control, in future multi-
center studies.
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